Synthesis and Design of Purpurin-18-Loaded Solid Lipid Nanoparticles for Improved Anticancer Efficiency of Photodynamic Therapy

Yeo, Sooho; Song, Hyeon Ho; Kim, Min Je; Hong, Seongwon; Yoon, Il; Lee, Woo Kyoung

doi:10.3390/pharmaceutics14051064

Cited by 10 publications

(11 citation statements)

References 42 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MPPa was loaded into SLN using a modified oil-in-water (O/W) emulsion method 31 . To prepare the O-phase, MPPa was added to the heated lipid at 10 °C above the lipid melting point.…”

Section: Methodsmentioning

confidence: 99%

“…All 1 H-NMR experiments were performed using a Varian spectrometer (500 MHz, CDCl 3 ) at the Biohealth Products Research Center, Inje University 31 , 32 .…”

Section: Methodsmentioning

confidence: 99%

“…The MPPa concentration was determined using a UV–Vis spectrophotometer (S-3100, Scinco, Seoul, Korea) at ambient temperature 31 , 32 . To determine the maximum absorption wavelength of MPPa, the absorption spectrum was measured in the wavelength range 300–800 nm.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Improved anticancer efficacy of methyl pyropheophorbide-a–incorporated solid lipid nanoparticles in photodynamic therapy

Yeo

Lee²,

Kim

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a promising anticancer treatment because it is patient-friendly and non-invasive. Methyl pyropheophorbide-a (MPPa), one of the chlorin class photosensitizers, is a drug with poor aqueous solubility. The purpose of this study was to synthesize MPPa and develop MPPa-loaded solid lipid nanoparticles (SLNs) with improved solubility and PDT efficacy. The synthesized MPPa was confirmed 1H nuclear magnetic resonance (1H-NMR) spectroscopy and UV–Vis spectroscopy. MPPa was encapsulated in SLN via a hot homogenization with sonication. Particle characterization was performed using particle size and zeta potential measurements. The pharmacological effect of MPPa was evaluated using the 1,3-diphenylisobenzofuran (DPBF) assay and anti-cancer effect against HeLa and A549 cell lines. The particle size and zeta potential ranged from 231.37 to 424.07 nm and − 17.37 to − 24.20 mV, respectively. MPPa showed sustained release from MPPa-loaded SLNs. All formulations improved the photostability of MPPa. The DPBF assay showed that SLNs enhanced the 1O2 generation from MPPa. In the photocytotoxicity analysis, MPPa-loaded SLNs demonstrated cytotoxicity upon photoirradiation but not in the dark. The PDT efficacy of MPPa improved following its entrapment in SLNs. This observation suggests that MPPa-loaded SLNs are suitable for the enhanced permeability and retention effect. Together, these results demonstrate that the developed MPPa-loaded SLNs are promising candidates for cancer treatment using PDT.

show abstract

“…MPPa was loaded into SLN using a modified oil-in-water (O/W) emulsion method 31 . To prepare the O-phase, MPPa was added to the heated lipid at 10 °C above the lipid melting point.…”

Section: Methodsmentioning

confidence: 99%

“…All 1 H-NMR experiments were performed using a Varian spectrometer (500 MHz, CDCl 3 ) at the Biohealth Products Research Center, Inje University 31 , 32 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Improved anticancer efficacy of methyl pyropheophorbide-a–incorporated solid lipid nanoparticles in photodynamic therapy

Yeo

Lee²,

Kim

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…104 Purpurin-18-loaded SLNs were designed with improved anticancer effects and bioavailability for photodynamic therapy. 105 Besides, the positive results could be achieved by incorporating idarubicin and doxorubicin using SLNs in "P388/ADR leukemia cells" as well as in the "murine leukemia mouse model". 106 In one study, the encapsulation of paclitaxel and curcumin was performed using SLNs, with remarkable encapsulation efficiency (curcumin, 97.6%; paclitaxel, 95.8%) and suitable particle sizes (∼121.8 ± 1.69 nm).…”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

“…For instance, mitoxantrone-loaded SLNs have been introduced with reduced toxicity and enhanced bioavailability . Purpurin-18-loaded SLNs were designed with improved anticancer effects and bioavailability for photodynamic therapy . Besides, the positive results could be achieved by incorporating idarubicin and doxorubicin using SLNs in “P388/ADR leukemia cells” as well as in the “murine leukemia mouse model” .…”

Section: Advanced Nanosystems For Targeted Cancer Therapeuticsmentioning

confidence: 99%

Advanced Nanosystems for Cancer Therapeutics: A Review

Mohajer

Mirhosseini‐Eshkevari

Ahmadi

et al. 2023

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Since cancer has a very complex pathophysiology, existing cancer treatment strategies encounter several challenges such as the lack of specificity/selectivity, induction of multidrug resistance, and possible side effects/toxicity. A wide variety of organic, inorganic, and hybrid nanosystems have been designed with unique magnetic, thermal, mechanical, electrical, and optical properties for targeted cancer therapy. These advanced nanosystems with enhanced bioavailability, biocompatibility, and drug loading capacity have been developed for targeted cancer therapy to reduce toxicity and improve the targeting properties. In this context, challenges persist for their clinical translational studies and enhancement of their therapeutic efficiency as well as the optimization of synthesis conditions and large-scale production. In addition, despite promising preclinical results, the number of nanosystems available to patients is still very low, partly due to a lack of understanding of the differences among animal model species and humans that influence the behavior and functionality of these nanosystems. Regarding this, organ-on-a-chip platforms can significantly help in drug screening and delivery aspects in cancer/tumor cells as well as cancer modeling research; the organs-on-chip approach can also be helpful to analyze the cancer–immune cells interactions. Future studies should focus on the exploration of multifunctional nanosystems with synergistic chemo-photothermal, photothermal/photodynamic, and cancer immunotherapeutic potentials as well as smart nanosystems with theranostic capabilities. Herein, recent advancements pertaining to the applications of advanced nanosystems for cancer therapeutics are deliberated. Current obstacles and limitations hindering the application from research to clinical uses are also discussed while providing recommendations for a more efficient adoption of nanomaterials in the treatment of cancers.

show abstract